8-K: Outlook Therapeutics Reports Q2 Fiscal Year 2025 Financial Results and Provides Corporate Update

Outlook Therapeutics remains on track for the planned commercial launch of LYTENAVA in Europe and anticipates a potential FDA approval decision in the U.S. for ONS-5010 in Q3 2025.

Summary

• Outlook Therapeutics reported its financial results for the second quarter of fiscal year 2025, ended March 31, 2025.
• The company is preparing for the commercial launch of LYTENAVA (bevacizumab gamma) in Germany and the UK in Q2 CY2025.
• The FDA has a PDUFA goal date of August 27, 2025, for a decision on ONS-5010 / LYTENAVA (bevacizumab-vikg) for the treatment of wet AMD in the United States.
• The net loss attributable to common stockholders for the quarter was $46.4 million, or $1.50 per share, compared to a net loss of $114.3 million, or $8.01 per share, for the same period last year.
• Adjusted net loss attributable to common stockholders for the quarter was $12.5 million, or $0.40 per share, compared to an adjusted net loss of $22.1 million, or $1.55 per share, for the same period last year.
• As of March 31, 2025, Outlook Therapeutics had cash and cash equivalents of $7.6 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in Europe with LYTENAVA's approval and planned launch, as well as the FDA's acceptance of the BLA resubmission. However, the net loss and limited cash reserves temper the overall sentiment.

Positives

• LYTENAVA has received marketing authorization in the EU and UK.
• NICE has recommended LYTENAVA for the treatment of wet AMD.
• The FDA has accepted the resubmitted BLA for ONS-5010 and set a PDUFA goal date.
• The company is on track for commercial launch in Europe.
• The net loss decreased significantly compared to the same quarter last year (from $114.3 million to $46.4 million).

Negatives

• The company reported a net loss of $46.4 million for the quarter.
• The company had cash and cash equivalents of only $7.6 million as of March 31, 2025.

Risks

• The FDA may not approve the ONS-5010 BLA.
• Pricing and reimbursement approval is needed in certain European Union Member States before ONS-5010/LYTENAVA can be sold.
• The company's limited cash resources may impact its ability to execute its commercialization plans.

Future Outlook

Outlook Therapeutics anticipates the commercial launch of LYTENAVA in Germany and the UK in Q2 CY2025 and potential FDA approval of ONS-5010 in the U.S. in Q3 CY2025.

Management Comments

• We continue to build momentum and remain laser focused on our goal of providing patients, physicians and payers with a much needed, approved ophthalmic formulation of bevacizumab, commented Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer of Outlook Therapeutics.

Industry Context

The announcement highlights the potential for LYTENAVA to capture a significant share of the bevacizumab market, currently dominated by off-label use. The company's strategic collaboration with Cencora is aimed at supporting market access and efficient distribution.

Comparison to Industry Standards

• Currently, off-label repackaged bevacizumab is one of the most frequently used first-line anti-VEGF treatments in Europe (approximately 2.8 million injections annually) and the United States (approximately 2.7 million injections annually) for the treatment of retinal diseases.
• LYTENAVA aims to compete with existing treatments like ranibizumab (Lucentis) and aflibercept (Eylea) by offering an approved ophthalmic formulation of bevacizumab.

Stakeholder Impact

• Successful commercialization of LYTENAVA would provide retina specialists with an approved ophthalmic formulation of bevacizumab.
• Patients with wet AMD would have access to a potentially safer and more convenient treatment option.
• Payers would have a new treatment option to consider for reimbursement.

Next Steps

• Initiate commercial launches in Germany and the UK in Q2 CY2025.
• Await FDA decision on ONS-5010 BLA by the PDUFA goal date of August 27, 2025.
• Potentially seek authorization in other European countries, Japan, and elsewhere.

Key Dates

Keywords

LYTENAVA, ONS-5010, bevacizumab, wet AMD, FDA, PDUFA, BLA, Outlook Therapeutics, Financial Results, Commercial Launch